Haruka Itakura, MD
Medical Oncology · Stanford, CANPI 1669413449
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,500 of the $4,728 with a category attached, or 95.2%. Pfizer accounts for 97.2% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 5 payments — averaging $945.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- Caris MPI, Inc.$130
Across 21 payments — averaging $9491.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$199K
What the payments were for
- Speaking & faculty fees$4,50095%
- Food & beverage$2285%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 4 | $4,597 |
| Caris MPI, Inc. | 1 | $130 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TUKYSA$4,500
- MI CANCER SEEK$130
How this compares
$4,728 in reported general payments places this provider in the 50th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrserduElacestrant Hcl | 12 | $277,236 |
| LapatinibLapatinib Ditosylate | 13 | $65,686 |
| Anastrozole | 20 | $2,003 |
| Exemestane | 17 | $1,282 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Stanford
- Ronald LevyStanford$475K
- Mark PegramStanford$374K
- Saad Munib Ahmed KhanStanford$262K
- Sandhya SrinivasStanford$220K
- Joel NealStanford$199K
- Gabriel MannisStanford$171K
- Lipika GoyalStanford$166K
- Melinda TelliStanford$137K
- Ranjana AdvaniStanford$113K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.